Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Never start, stop, or change any medication without direct guidance from your prescribing healthcare provider.

GLP-1 Medications: Ozempic, Mounjaro, and Beyond

Creator: Editorial Team
Published: 2026-03-28

Last updated: March 2026 | Reviewed by MDTalks Editorial Team

GLP-1 receptor agonists have become one of the most important medication classes in diabetes care. Originally developed for type 2 diabetes, these drugs have demonstrated remarkable benefits that extend far beyond glucose control, including significant weight loss, cardiovascular risk reduction, and kidney protection. The 2026 ADA Standards of Care now position GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists as central treatment options for patients with type 2 diabetes who also have obesity, cardiovascular disease, heart failure, or metabolic liver disease.

How GLP-1 Medications Work

GLP-1 (glucagon-like peptide-1) is a natural hormone released by the intestines after eating. It stimulates insulin secretion in a glucose-dependent manner (meaning it works when blood sugar is elevated but does not cause insulin release when glucose is normal, reducing hypoglycemia risk). GLP-1 receptor agonists mimic and amplify this hormone’s effects:

Stimulate insulin secretion when blood sugar is high
Suppress glucagon release (glucagon raises blood sugar)
Slow gastric emptying, which reduces post-meal glucose spikes and increases satiety
Act on brain appetite centers, reducing hunger and food intake

Dual GIP/GLP-1 receptor agonists (like tirzepatide) activate both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, providing enhanced glucose lowering and weight loss compared to GLP-1 agonists alone.

Currently Available GLP-1 and Dual Agonist Medications

Medication	Brand Name(s)	Frequency	A1C Reduction	Weight Loss	Cardiovascular Benefit
Semaglutide (injectable)	Ozempic (diabetes), Wegovy (weight)	Weekly injection	1.0%–1.8%	10%–15% body weight	Proven (SUSTAIN/SELECT trials)
Semaglutide (oral)	Rybelsus	Daily pill	0.9%–1.4%	5%–8% body weight	Under study; likely similar
Tirzepatide	Mounjaro (diabetes), Zepbound (weight)	Weekly injection	1.5%–2.4%	15%–22% body weight	Proven (SURPASS trials)
Liraglutide	Victoza (diabetes), Saxenda (weight)	Daily injection	0.8%–1.2%	5%–8% body weight	Proven (LEADER trial)
Dulaglutide	Trulicity	Weekly injection	0.8%–1.6%	3%–5% body weight	Proven (REWIND trial)
Exenatide ER	Bydureon BCise	Weekly injection	0.8%–1.6%	2%–4% body weight	Neutral

A1C reduction and weight loss figures are approximate ranges from clinical trials and may vary by dose and individual.

Beyond Glucose: Cardiovascular and Kidney Benefits

One of the most significant developments in diabetes care has been the discovery that GLP-1 receptor agonists reduce cardiovascular events independently of their glucose-lowering effect.

Cardiovascular risk reduction: Long-acting GLP-1 receptor agonists reduce the incidence of major adverse cardiovascular events, hospitalization for heart failure, and all-cause mortality in people with type 2 diabetes.
Kidney protection: GLP-1 agonists slow the progression of diabetic kidney disease and reduce the risk of kidney events.
Blood pressure reduction: Modest reductions in systolic blood pressure (2–5 mmHg) have been observed across trials.
Lipid improvements: Reductions in triglycerides and modest improvements in other lipid markers.

The 2026 ADA Standards now include GLP-1 receptor agonists and dual GIP/GLP-1 agonists for glycemic management in patients with type 2 diabetes who also have symptomatic heart failure with preserved ejection fraction (HFpEF), metabolic-associated steatotic liver disease (MASLD/MASH), or obesity.

For more on cardiovascular risk, see Diabetes and Heart Disease: Reducing Your Risk.

Side Effects

Common

Nausea (the most frequent side effect; usually decreases over 4–8 weeks)
Vomiting and diarrhea
Constipation
Abdominal discomfort
Injection site reactions (injectable forms)

Starting at a low dose and titrating slowly (as prescribed) reduces GI side effects significantly.

Less Common but Important

Pancreatitis: Rare. Symptoms include severe abdominal pain radiating to the back. Seek immediate medical attention.
Gallbladder disease: Increased risk of gallstones, especially with rapid weight loss.
Thyroid concerns: GLP-1 agonists carry a boxed warning about thyroid C-cell tumors observed in rodent studies. The clinical relevance in humans is unclear, but these medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Hypoglycemia

GLP-1 agonists alone rarely cause hypoglycemia. However, when combined with insulin or sulfonylureas, the risk increases. Dose adjustments of the other medications may be needed.

Cost and Access

GLP-1 receptor agonists are among the most expensive diabetes medications:

Without insurance: Approximately $800 to $1,300+ per month for branded injectables.
With insurance: Copays vary widely. Many plans cover these medications for diabetes but may restrict access for weight loss indications.
Manufacturer programs: Novo Nordisk and Eli Lilly offer savings cards and patient assistance programs for eligible patients.
Compounding: Following the FDA’s removal of semaglutide and tirzepatide from the drug shortage list in early 2025, compounded versions are no longer available under shortage exemptions.

Cost remains a significant barrier. Discuss insurance coverage and manufacturer programs with your pharmacy and healthcare provider.

What’s Coming Next

The GLP-1 pipeline is expanding rapidly:

CagriSema (semaglutide + cagrilintide): Combines a GLP-1 agonist with an amylin analog for enhanced glucose and weight effects.
Orforglipron: An oral non-peptide GLP-1 agonist that could be cheaper to manufacture than injectable forms.
Retatrutide: A triple agonist (GLP-1/GIP/glucagon) in late-stage trials showing unprecedented weight loss.
Survodutide: A dual GLP-1/glucagon agonist in trials for diabetes, obesity, and liver disease.

These next-generation agents may offer even greater efficacy and potentially broader access.

For the broader medication landscape, see Metformin: What Every Diabetic Should Know and SGLT2 Inhibitors: How They Work for Diabetes. For comprehensive management, see the Complete Guide to Diabetes Management in 2026.

Key Takeaways

GLP-1 receptor agonists lower blood sugar, promote significant weight loss, and reduce cardiovascular and kidney disease risk.
Tirzepatide (Mounjaro) offers the greatest A1C reduction and weight loss among currently available agents.
The 2026 ADA Standards have expanded GLP-1 agonist recommendations to include patients with heart failure, liver disease, and obesity.
Nausea is the most common side effect but typically improves with dose titration.
Cost remains a major barrier; explore insurance coverage and manufacturer assistance programs.
These medications are prescription-only and should be started and managed by your healthcare provider as part of a comprehensive diabetes treatment plan.

Sources

American Diabetes Association. “9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care — 2026.” Diabetes Care, Vol. 49, Suppl. 1, January 2026. diabetes.org
National Center for Biotechnology Information. “GLP-1 Receptor Agonists: Pharmacology and Therapeutic Applications.” StatPearls, updated 2025. ncbi.nlm.nih.gov
American Diabetes Association. “GLP-1 Weight Loss Drugs 2026 Guide.” diabetes.org

This article is part of the MDTalks Diabetes Hub. See also GLP-1 Weight Loss Drugs 2026 Guide and AI Answers About Diabetes.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Never start or change medications without consulting your healthcare provider.